Wilson Sonsini Goodrich & Rosati advised Dren Bio on the transaction. Dren Bio, Inc., a privately held, clinical-stage biopharmaceutical company developing antibody therapeutics for cancer, autoimmune,...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented InduPro in the transaction. InduPro, Inc., a biotechnology company announced an $85 million Series A financing co-led by The Column...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Rubedo Life Sciences on the transaction. Rubedo Life Sciences (Rubedo), a biopharmaceutical company, announced it closed a $40M Series A...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Neurona Therapeutics on the transaction. Neurona Therapeutics announced it closed a $120 million financing co-led by Viking Global Investors and Cormorant...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented Alector in the offering, and Davis Polk & Wardwell represented the sole book-running manager and underwriter, Cantor Fitzgerald & Co....
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised ALX Oncology Holdings Inc. on the offering, and Cooley advised the underwriters. ALX Oncology Holdings Inc. (Nasdaq:ALXO) announced the pricing...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Novo Holdings A/S and Vida Ventures on the transaction. Avalyn Pharma Inc. announced the closing of an oversubscribed $175 million...
You must be a Standard 1 Year member to access this content.
Fox Rothschild LLP is acting as legal advisor to Cyclo Therapeutics and Wilson Sonsini Goodrich & Rosati, P.C. is acting as legal advisor to Applied Molecular...
You must be a Standard 1 Year member to access this content.
Sidley Austin LLP advised Pyxis Oncology, Inc. on the transaction, while Wilson Sonsini advised Apexigen on the transaction. Pyxis Oncology, Inc., a clinical-stage company, and Apexigen,...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Switch Therapeutics on the transaction and launch. Switch Therapeutics, a preclinical stage biotechnology company pioneering a new way to use...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Cajal Neuroscience on the deal. Cajal Neuroscience Inc., a biotechnology company integrating human genetics, functional genomics, and advanced microscopy to...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini advised Kedalion Therapeutics on the deal. Novartis announced that it acquired Kedalion Therapeutics and its AcuStream technology, an innovative device that may have the...
You must be a Standard 1 Year member to access this content.
